Laurie Doyle

Contatto Relazioni con gli Investitori presso GPC Biotech, Inc.

Health Technology

Retail Trade

Profilo

Ms. Laurie Doyle is a Director-Corporate Communications at GPC Biotech, Inc. and a Director-Corporate Communications at Transgene SA. Ms. Doyle was previously employed as Senior Director-US Investor Relations by Agennix AG.

Posizioni attive di Laurie Doyle

Società	Posizione	Inizio
GPC Biotech, Inc. GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA.	Contatto Relazioni con gli Investitori	-

Tutte le posizioni attive di Laurie Doyle

Precedenti posizioni note di Laurie Doyle

Società	Posizione	Fine
TRANSGENE	Public Communications Contact	-
AGENNIX AG	Public Communications Contact	-

Vedi nel dettaglio l'esperienza di Laurie Doyle

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Laurie Doyle

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
TRANSGENE	Health Technology

Aziende private	2
GPC Biotech, Inc. GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA.	Retail Trade
Agennix AG Agennix AG BiotechnologyHealth Technology Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany.	Health Technology